CardioCare
Reimagining heart and vascular health through proactive, personalized prevention powered by smart diagnostics and real-world data.
🇨🇳 Focused first on China, where heart disease leads all causes of death.
Get UpdatesThe Problems We're Tackling
Massive Burden of Heart Disease
Cardiovascular disease is the leading cause of death globally—and in China, it accounts for nearly half of all deaths. Over 330 million people are affected, imposing over $300 billion in annual healthcare costs. There is an urgent need for better preventive care and early intervention.
Poor Early Detection
Existing risk assessment tools, mainly designed for Western populations, lack accuracy for East Asians. Advanced technologies like multi-omics profiling and digital phenotyping are promising but not integrated into clinical practice, leaving early intervention opportunities missed.
Limited Primary Care Infrastructure
China’s primary care system struggles to manage chronic conditions like cardiovascular disease. Most heart disease cases are linked to modifiable factors — diet, exercise, smoking — yet patients rarely receive support to manage these risks. With 1 billion+ mobile users, digital health platforms could deliver scalable, personalized prevention, but remain vastly underutilized.
Stagnant Drug Development
Innovation in cardiovascular drug treatments has largely stalled, with few new therapies emerging in decades. Investment in cardiovascular R&D remains low, partly due to costly clinical trials and regulatory hurdles, especially for therapies tailored to East Asian populations.
Our Solution
AI Risk Prediction & Blood Testing
Built for East Asian populations, our prediction engine integrates blood, clinical, and wearables data to calculate a cardiovascular disease risk score for each user, enabling personalized intervention. We’re also developing a blood test kit to enable early risk detection.
Digital Health Management App
A mobile platform that turns health data into daily guidance—offering personalized advice on diet, activity, and lifestyle. Real-time updates from wearables and self-reported habits help users stay on track and manage their cardiovascular health between clinic visits.
Commercial Biobank & Platform
With consent, user biosamples and health data feed into a secure biobank—linking biology to real-world outcomes. This growing resource powers drug discovery, drives research partnerships, and continuously improves our AI model for precision prevention.
Who We Are
Built by a team of scientists who care deeply about tackling chronic disease — starting with the heart ❤️
Hanyu Wang
Co-founder & CEO
Leads strategy, risk prediction, and clinical collaborations.
AboutAfter undergraduate studies at Peking University, Hanyu earned an MPhil from the University of Cambridge and is currently completing his PhD at the University of Oxford, focusing on cardiovascular risk factors using large-scale, population-based databases with a special emphasis on Chinese and European populations. His background includes working with UNICEF on global child protection policies, applying quantitative methods to evaluate new health technologies at the Bristol Technology Assessment Group, and integrating wearables with advanced algorithms for cardiovascular risk management at Imperial-NTU Medical School.
Henderson Zhu
Co-founder & Chief Scientist
Diagnostics development and lab operations in China.
AboutHenderson holds a BSc in Biochemistry from Imperial College London and an MPhil in Medical Science from the University of Cambridge. He completed his PhD at the University of Oxford (Oxford Vaccine Group), where his work focused on clinical evaluation and translational development of vaccines and immunoassays. Henderson brings expertise in designing high-throughput serological tests and multi-omics profiling pipelines, with experience spanning preclinical validation to clinical trial settings. His work supports the rigorous development of diagnostic tools and quality systems for CardioCare’s testing platform.
Charles Li
Co-founder & CTO
Digital health, data science, and North America partnerships.
AboutCharles trained in molecular biology and data science at UC Berkeley and is now pursuing a PhD at the University of Oxford, where he studies the genetic and environmental drivers of age-related eye diseases in Chinese and European populations. He has overseen epidemiological studies and data analytics for a multimillion-patient clinical disease registry at the American Academy of Ophthalmology and previously contributed to research collaborations on infectious disease surveillance between UC Berkeley and China’s CDC. His work bridges population-scale data, real-world evidence, and precision health.
Partnerships
We are actively seeking partners across healthcare, technology, research, and policy to help us scale our impact.
Hospitals & Clinics
We’re partnering with care providers for patient recruitment, lab support, and real-world deployment.
Wearables & Apps
We seek platform integrations that expand reach and enrich our real-time data streams.
Pharma & Therapeutics
We're open to co-developing insights and IP around precision medicine and drug discovery.
Academic Collaborators
We welcome research partnerships to validate models and publish impactful science.
Policy & Regulation
We’re building proactive relationships with regulators to ensure safe, ethical deployment.
Investors
We’re currently raising our pre-seed round and welcome mission-aligned backers.
Reach out to learn more
Join us on our mission to transform cardiovascular health through earlier detection and smarter prevention. Whether you're seeking more information, exploring partnership opportunities, or just want to say hello—we'd love to hear from you.
Contact us to explore how we can make a difference together.